Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...

By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...

Autoimmune diseases make the immune system attack healthy tissues. These can affect organs like kidneys, leading to ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Discover the five major risk factors for kidney disease, from daily habits to genetic predisposition, and learn the warning ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA ...